Diebold Nixdorf, Incorporated (DBD) Earnings History
Profitable37 years of earnings data (1989–2025) · Positive TTM net income
Loading earnings history...
Diebold Nixdorf, Incorporated (DBD) Earnings Overview
As of July 7, 2026, Diebold Nixdorf, Incorporated (DBD) reported trailing twelve-month net income of $110M, reflecting +677.3% year-over-year growth. The company earned $3.07 per diluted share over the past four quarters, with a net profit margin of 2.5%.
Looking at the long-term picture, DBD's historical earnings data spans multiple years. The company achieved its highest annual net income of $1.38B in fiscal 2023.
Diebold Nixdorf, Incorporated maintains positive profitability with a gross margin of 26.4%, operating margin of 8.8%, and net margin of 2.5%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including NATL ($176M net income, 3.7% margin), PAX ($86M net income, 22.3% margin), FIS ($2.67B net income, 3.6% margin), DBD has room to improve margins relative to the peer group. Compare DBD vs NATL →
DBD Earnings vs Peers
Earnings metrics vs comparable public companies
DBD Historical Earnings Data (1989–2025)
37 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $95M | +673.3% | $335M | $2.54 | 2.5% | 8.8% |
| 2024 | -$17M | -101.2% | $182M | $-0.44 | -0.4% | 4.9% |
| 2023 | $1.38B | +336.7% | $87M | $21.38 | 36.6% | 2.3% |
| 2022 | -$581M | -637.8% | -$212M | $-7.44 | -16.8% | -6.1% |
| 2021 | -$79M | +70.7% | $137M | $-1.00 | -2.0% | 3.5% |
| 2020 | -$269M | +21.2% | $24M | $-3.47 | -6.9% | 0.6% |
| 2019 | -$341M | +40.0% | $235M | $-4.51 | -7.7% | 5.3% |
| 2018 | -$569M | -135.5% | -$363M | $-7.48 | -12.4% | -7.9% |
| 2017 | -$242M | -35.7% | $135M | $-3.20 | -5.2% | 2.9% |
| 2016 | -$178M | -331.8% | $61M | $-2.58 | -5.4% | 1.8% |
| 2015 | $77M | -32.9% | $134M | $1.12 | 3.2% | 5.6% |
| 2014 | $114M | +163.0% | $181M | $1.76 | 3.8% | 5.9% |
| 2013 | -$182M | -331.5% | -$118M | $-2.85 | -6.4% | -4.1% |
| 2012 | $78M | -45.8% | $125M | $1.23 | 2.6% | 4.2% |
| 2011 | $145M | +815.1% | $156M | $2.24 | 5.1% | 5.5% |
| 2010 | -$20M | -148.7% | -$2M | $-0.31 | -0.7% | -0.1% |
| 2009 | $42M | -55.5% | $151M | $0.62 | 1.5% | 5.5% |
| 2008 | $93M | +136.4% | $176M | $1.41 | 2.9% | 5.6% |
| 2007 | $40M | -54.3% | $99M | $0.59 | 1.3% | 3.4% |
| 2006 | $87M | -10.5% | $176M | $1.55 | 3.0% | 6.0% |
| 2005 | $97M | -47.4% | $161M | $1.43 | 3.7% | 6.2% |
| 2004 | $184M | +5.3% | $277M | $2.53 | 7.7% | 11.6% |
| 2003 | $175M | +76.3% | $263M | $2.37 | 8.3% | 12.5% |
| 2002 | $99M | +48.2% | $241M | $1.37 | 5.1% | 12.4% |
| 2001 | $67M | -51.1% | $139M | $0.93 | 3.8% | 7.9% |
| 2000 | $137M | +6.2% | $229M | $1.92 | 7.9% | 13.1% |
| 1999 | $129M | +69.4% | $185M | $1.85 | 10.2% | 14.7% |
| 1998 | $76M | -37.9% | $167M | $1.10 | 6.4% | 14.1% |
| 1997 | $123M | +25.8% | $184M | $1.76 | 10.0% | 15.0% |
| 1996 | $97M | +27.8% | $140M | $1.42 | 9.5% | 13.6% |
| 1995 | $76M | +20.0% | $107M | $1.67 | 8.8% | 12.4% |
| 1994 | $64M | +31.2% | $91M | $2.09 | 8.4% | 11.9% |
| 1993 | $48M | +108.6% | $69M | $0.71 | 7.8% | 11.1% |
| 1992 | $23M | -35.0% | $54M | $0.35 | 4.3% | 9.9% |
| 1991 | $36M | +31.7% | $44M | $0.53 | 7.1% | 8.8% |
| 1990 | $27M | -25.1% | $32M | $0.41 | 5.7% | 6.8% |
| 1989 | $36M | - | $46M | $0.54 | 7.7% | 9.7% |
Download Data
Export DBD earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
37+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DBD — Frequently Asked Questions
Quick answers to the most common questions about buying DBD stock.
What is DBD earnings per share (EPS)?
DBD trailing twelve-month (TTM) diluted EPS is $3.07, reflecting +677.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1989 to 2025 is available in the table on this page.
What is Diebold Nixdorf, Incorporated's net income?
Diebold Nixdorf, Incorporated (DBD) trailing twelve-month net income is $110M as of 2025. Earnings grew +677.3% year-over-year.
Is DBD profitable?
Yes, DBD is profitable with a TTM net income of $110M and a net profit margin of +2.5%.
What is DBD's earnings growth rate?
DBD compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: +8.5%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1989 to 2025.
What are DBD's profit margins?
Diebold Nixdorf, Incorporated net profit margin is +2.5%, operating margin is +8.8%, and gross margin is +26.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is +9.3%.
Is DBD growing earnings?
Yes, DBD earnings are accelerating — EPS growth of +677.3% exceeds the 5-year CAGR of N/A. TTM net income reached $110M. Earnings momentum is strengthening.
What was DBD's best earnings year?
Diebold Nixdorf, Incorporated's highest annual net income on record is $1.4B, achieved in fiscal year 2023. Earnings history on this page spans 1989 to 2025 and includes all annual and quarterly figures.
What were DBD's earnings last quarter?
DBD's most recent reported quarter was Q1 2026. Net income was $7M with diluted EPS of $0.14. For a full breakdown of all quarters, see the quarterly earnings table on this page.